San Diego, CA -- (SBWIRE) -- 07/29/2016 -- A deadline is coming up on August 1, 2016 in the lawsuit filed for investors of Eagle Pharmaceuticals Inc (NASDAQ:EGRX over alleged securities laws violations by Eagle Pharmaceuticals Inc.

Investors who purchased shares of Eagle Pharmaceuticals Inc (NASDAQ:EGRX) have certain options and there are strict and short deadlines running. Deadline: August 1, 2016. NASDAQ:EGRX stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

According to the complaint filed in the U.S. District Court for the District of New Jersey the plaintiff alleges on behalf of purchasers of Eagle Pharmaceuticals Inc (NASDAQ:EGRX) common shares between February 23, 2016 and March 18, 2016, that the defendants violated Federal Securities Laws.

On February 25, 2016, Eagle Pharmaceuticals Inc reported its fourth quarter and full year 2015 results. Eagle Pharmaceuticals Inc reported that its Total Revenue rose from $19.10 million for the 12 months period that ended on September 30, 2014 to $66.23 million for the 12 months period that ended on December 31, 2015 and that its Net Loss of $17.98 million for the 12 months period that ended on September 30, 2014 turned into a Net Income of $2.57 million for the 12 months period that ended on December 31, 2015. On February 25, 2016, Eagle Pharmaceuticals' CEO stated, regarding the pending New Drug Application ("NDA") for the Company's anticoagulant drug KANGIO™, "We have been interacting with FDA and we are preparing for launch, everything seems to be on track for a March 19 approval, and we anticipate shipping in late Q1 or early Q2."

Then, on March 18, 2016, Eagle Pharmaceuticals announced that it had received a Complete Response Letter from the FDA stating that the FDA "cannot approve the application in its present form and requested additional information" regarding the substances used in KANGIO™.

Shares of Eagle Pharmaceuticals Inc (NASDAQ:EGRX) declined to as low as $35.10 per share on March 28, 2016.

On July 28, 2016, NASDAQ:EGRX shares closed at $44.76 per share.

Those who purchased shares of Eagle Pharmaceuticals Inc have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com